| Friday, 16 April 2004 Saturday, 17 April 2004 |
||
| Organisers | N. Georgiou (Utrecht, The Netherlands) G. Kontoghiorghes (Limassol, Cyprus) A. Kolnagou (Limassol, Cyprus) |
|
| Sponsors | Apotex Inc. (Ontario, Canada) Thalassaemia International Federation (Nicosia, Cyprus) European Iron Club International Bioiron Society Associazione per la Ricerca “Piera Cutino” (Italy) Schwarz Pharma (Monheim, Germany) |
|
Oral iron chelators in the treatment of thalassaemias and other diseases
|
||
| Session I | Advances in the treatment of iron overload with deferiprone, deferoxamine and their combination | Friday morning |
| Chairs | R. Galanello (Cagliari, Italy) G. Fiorelli (Milan, Italy) |
abstract number |
| 08.30 – 08.50 | Combined long-term oral and parenteral iron chelation R. Origa, C. Dessì, E. Defraia, M.G. Crobu, G.B. Leoni, P.P. Muroni, P. Bina, and R. Galanello (Cagliari, Italy) |
142 |
| 08.50 – 09.10 | Comparison between monotherapy and combined iron chelation therapy in thalassaemic patients S. Fragatou, C. Richardson, and C. Politis (Athens, Greece) |
145 |
| 09.10 – 09.30 | New approach to iron chelation therapy using effective deferiprone therapy or combination with deferoxamine A. Kolnagou, and G. J. Kontoghiorghes (Limassol, Cyprus) |
148 |
| 09.30 – 09.50 | Deferiprone in patients with ß-thalassemia major for four years in the Chinese population in Taiwan C.T. Peng, K.H. Wu, C.C. Tsai, and C.H. Tsai (Taichung, Taiwan) |
138 |
| 09.50 – 10.10 | Long-term study of the toxicity of deferiprone in iron-loaded and naive monkeys: impact of divided daily dosing J. Connelly, J. Yang, F. Tricta, and M. Spino (Toronto, Ontario, Canada) |
151 |
| 10.10 – 11.15 | coffee break + plenary lecture | |
| Session II | NTBI measurements in thalassaemia | |
| Chairs | G. Kontoghiorghes (Limassol, Cyprus) A. Kolnagou (Paphos, Cyprus) |
|
| 11.30 – 11.50 | NTBI values in thalassemia patients on combined chelation (DFO+L1) or on monotherapy (DFO or L1) A. Meo, M.A. LaRosa, L.Zanghì, L. Duca, I. Nava, and M.D. Cappellini (Milan, Italy) |
149 |
| 11.50 – 12.10 | Results of an international round robin for serum Non Transferrin-Bound Iron measurements E.M.G. Jacobs, W. Breuer, Z.I. Cabantchik, P.J. Evans, E.H.J.M. Jansen, R.C. Hider, D.Y. Liu, B. Scheiber, B. Sturm, K. Jauhiainen, L. von Bonsdorff, J.C.M. Hendriks, L.J.H. van Tits, and D.W. Swinkels (Nijmegen, The Netherlands: Jerusalem, Israel; London, UK; Bilthoven, The Netherlands; Vienna, Austria; Helsinki, Finland) |
143 |
| Session III | Synthesis, pharmacology and status of iron chelators in development | |
| 12.10 – 12.30 | Pharmacodynamics of repeat dose oral administration of GT56-252 in iron-loaded Cebus monkeys M.P. Bree, J.L. Wagner, J. Bell, and J.K. Marquis (Waltham, MA, USA; Homestead, FL, USA ) |
226 |
| 12.30 – 12.50 | The safety and pharmacokinetics of GT56-252, a novel orally available iron chelator J.M. Donovan, P.A. Palmer, M.A. Plone, and B. Wonke (Waltham, MA, USA; Berkshire, UK; London, UK) |
139 |
| 12.50 – 13.10 | Development of the new oral chelators ICL670, L1NAll and GT56-252 and comparison with the iron chelating drugs deferiprone and deferoxamine G.J. Kontoghiorghes, K. Pattichis, K. Neocleous, and A. Kolnagou (Limassol, Cyprus) |
147 |
| 13.10 – 14.45 | lunch / poster viewing / exhibition + ESCI Award lecture | |
| Session IV | ICOC selected poster presentations | Friday afternoon |
| Chairs | B.S. van Asbeck (Utrecht, The Netherlands) C. De Luca (Rome, Italy) |
|
| 15.00 – 15.10 | Hydroxyurea for thalassemia intermedia: a one center experience A. Mancuso, P. Rigano, D. Renda, V. Di Salvo, M.C. Renda, and A. Maggio (Palermo, Italy) |
228 |
| 15.10 – 15.20 | Non-Transferrin-Bound-Iron in subjects with normal transferrin saturation D.L. van der A, N.A. Georgiou, J.H. van Kats-Renaud, J.J.M. Marx, D.E. Grobbee, and Y.T. van der Schouw (Utrecht, The Netherlands) |
111 |
| 15.20 – 15.30 | Non-Transferrin Bound Iron alters adhesion of human monocytes to human vascular endothelium under shear stress A.E.R. Kartikasari, N.A. Georgiou, S. van Mullekom, F.L.J. Visseren, H. van Kats-Renaud, B.S. van Asbeck, and J.J.M. Marx (Utrecht, The Netherlands) |
116 |
| 15.30 – 15.40 | Comparison of MRI T2 and MRI T2* in the diagnosis of cardiac iron load in thalassaemia patients C. Economides, E. Eracleous, D. Yazman, A. Kolnagou, and G.J. Kontoghiorghes (Limassol, Cyprus) |
117 |
| 15.40 – 15.50 | How relevant are serum ferritin levels and MRI T2* for assessing cardiac iron load in thalassaemia A. Kolnagou, D. Yazman, C. Economides, E. Eracleous, and G.J. Kontoghiorghes ( Paphos, Limassol, Cyprus; Nicosia, Turkish Cyprus) |
118 |
| 15.50 – 16.00 | Flavonoids of Garcinia kola seeds inhibited Fe/ ascorbate- induced oxidation of human LDL in vitro: a comparative study O.A. Adaramoye, E.O. Farombi, E.O. Adeyemi, and G.O. Emerole (Ibadan, Al Ain, Nigeria) |
119 |
| 16.40 | end of session | |
| Session V | Iron metabolism in thalassaemias and other diseases | Saturday morning |
| Chairs | D.R. Richardson (Sydney, Australia) B. Scheiber-Mojdehkar (Vienna, Austria) |
Abstract number |
| 08.30 – 08.50 | Novel di-2-pyridyl-derived iron chelators with marked and selective anti-tumor activity: in vitro and in vivo assessment J. Yuan, D.B. Lovejoy, and D.R. Richardson (Sydney, Australia) |
146 |
| 08.50 – 09.10 | Iron chelators overcome N-Myc repression of NDRG1 in neuroblastoma cells L.A Castelnoble, N.T.V. Le, and D.R. Richardson (Sydney, Australia) |
140 |
| 09.10 – 09.30 | Potent iron chelators but not the DNA-damaging agent, actinomycin D, markedly up-regulate the metastasis suppressor gene, NDRG1 N.T.V. Le, and D.R. Richardson (Sydney, Australia) |
141 |
| 09.30 – 09.50 | Unexpected effects of Antimycin A on iron metabolism B. Scheiber-Mojdehkar, B. Sturm, T. Twaroch, B. Knapitsch, S. Czingraber, D. Staribacher, and H. Goldenberg (Vienna, Austria) |
144 |
| 09.50 – 10.10 | Diagnosis of aceruloplasminemia: a pediatric case F. Longo, A. Piga, F. Marletto, S. Bosio, and C. Camaschella (Turin, Italy) |
225 |
| 10.00 – 11.15 | coffee break + plenary lecture | |
| Session VI | Free radicals in biology and medicine: the role of antioxidants | |
| Chairs | L. Korkina (Moscow, Russia) N.A. Georgiou (Utrecht, The Netherlands) |
|
| 11.30 – 11.50 | The effect of deferiprone on essential elements level and parameters of oxidative stress in experiment in rats V. Eybl, D. Kotyzova, and M. Bludovska (Pilsen, Czech Republic) |
137 |
| 11.50 – 12.10 | Pro-/antioxidant formulations enhance antiviral defences in herpes simplex (type II) and zoster (type III) recurrent diseases: a controlled clinical-laboratory study L. Korkina, Z. Kharaeva, A. Luci, and C. De Luca (Moscow, Russia; Nal’chik, Russia; Rome, Italy) |
152 |
| 12.10 – 12.30 | Double-blind, randomized, placebo-controlled clinical study of a pro-/antioxidant formulation in recurrent viral warts C. De Luca, A. Luci, I. Deeva, I. Trakhtman, and L. Korkina (Rome, Italy; Moscow, Russia) |
153 |
| Session VII | Iron chelation therapy outcome: role of hereditary hemochromatosis | |
| 12.30 – 12.50 | Iron chelation treatment: role of iron metabolism genes M.C. Renda, A. Giambona, F. Leto, A. Morabito, D. Renda, G. D’Amico, E. D’Alcamo, A. Santoro, G. Cammarata, L. Gerace, A. Rizzo, and A. Maggio (Palermo, Milan, Monza, Italy) |
229 |
| 12.50 – 13.00 | discussion | |
| 13.00 – 14.00 | lunch / poster viewing / exhibition | |
| Session VIII | Future strategies and developments in iron chelation | Saturday afternoon |
| Chair | Z.I. Cabantchik (Jerusalem, Israel) J.J.M. Marx (Utrecht, The Netherlands) |
Abstract number |
| 14.00 – 14.40 | Methods of assessing iron overload: Time for reappraisal M. Spino, J. Connelly, and F. Tricta (Toronto, Ontario, Canada) |
150 |
| 14.40 – 15.20 | Redox activity of plasma non-transferrin bound iron (NTBI) and its susceptibility to chelation during oral cheation therapy P. Pootrakul, W. Breuer, P. Sirunkapracha, M. Sametband, C. Hershko, and Z.I. Cabantchik (Salaya, Thailand; Jerusalem, Israel) |
227 |
| 15.20 – 15.40 | Announcement of the 15th ICOC C.T. Peng (Taichung, Taiwan) and G.J. Kontoghiorghes (Limassol, Cyprus) |
|
| 15.40 | end of workshop | |
| Posters | ||
| Effect of iron on monocyte attachment to microorganism-infected human endothelial cells N.A. Georgiou, A.E. R. Kartikasari, M.C. de Geest, J.J.M. Bouwman, F.L. J. Visseren, B.S. van Asbeck, and J.J. M. Marx (Utrecht, The Netherlands) |
115 | |
| Progression of chronic active hepatitis to liver cirrhosis and hepatocellular carcinoma in a thalassaemic patient with low iron stores: a case report C. Politis, S. Fragatou, and G. Koskinas (Athens, Greece) |
154 | |
| Genetic modifiers of iron overload in H63D carriers: preliminary data P. Delbini, M.D. Cappellini, L. Duca, I. Nava, and G. Fiorelli (Milan, Italy) |
155 | |
| Genetic regulation of iron uptake and transfer in the mynah bird A. Mete, F. van Asten, G.M. Dorrestein, J.E. van Dijk, and J.J.M. Marx (Utrecht, The Netherlands) |
156 | |
